Showing results (571-580 of 583) with videos related to

Sort By:
Pageof 59
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2001
Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent modelsA Lecci, F Carini, M Tramontana, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptorA R Renzetti, R M Catalioto, M Criscuoli, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 6, 2001
Pro- and anti-inflammatory actions of ricinoleic acid: similarities and differences with capsaicinC Vieira, S Fetzer, S K Sauer, et al.
Canadian Journal of Physiology and Pharmacology|May 25, 2002
Cardiovascular effects of peptide kinin B2 receptor antagonists in ratsF Carini, M Guelfi, A Lecci, et al.
Biochemical Pharmacology|May 30, 2001
A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogueM Bigioni, C Salvatore, A Bullo, et al.
Chemical Research in Toxicology|December 22, 2000
Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metaboliteG Minotti, S Licata, A Saponiero, et al.
Neuropeptides|March 9, 2002
Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonistR Cirillo, M Astolfi, B Conte, et al.
Journal of Medicinal Chemistry|February 13, 1999
A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacersC Galoppini, S Meini, M Tancredi, et al.
Canadian Journal of Physiology and Pharmacology|May 25, 2002
In vitro and in vivo activity of analogues of the kinin B2 receptor antagonist MEN1 1270S Meini, A Lecci, F Carini, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2010
Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonistG Villetti, F Pastore, M Bergamaschi, et al.
Pageof 59